Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2015

Conditions
Post-Traumatic Stress Disorder
Interventions
DRUG

Tramadol

Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).

DRUG

Placebo

Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).

Trial Locations (1)

45220

Cincinnati VA Medical Center, Cincinnati

All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium

OTHER

NCT01517711 - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter